<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">32724</article-id><article-id pub-id-type="doi">10.7554/eLife.32724</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group></article-categories><title-group><article-title>RNA-dependent RNA targeting by CRISPR-Cas9</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-99674"><name><surname>Strutt</surname><given-names>Steven C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-99675"><name><surname>Torrez</surname><given-names>Rachel M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99676"><name><surname>Kaya</surname><given-names>Emine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99677"><name><surname>Negrete</surname><given-names>Oscar A</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-3402"><name><surname>Doudna</surname><given-names>Jennifer A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9161-999X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><institution content-type="dept">Department of Molecular and Cell Biology</institution>, <institution>University of California, Berkeley</institution>, <addr-line><named-content content-type="city">Berkeley</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Biotechnology and Bioengineering Department</institution>, <institution>Sandia National Laboratories</institution>, <addr-line><named-content content-type="city">Livermore</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-19873"><name><surname>Barrangou</surname><given-names>Rodolphe</given-names></name><role>Reviewing editor</role><aff><institution>North Carolina State University</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>doudna@berkeley.edu</email> (JD);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>05</day><month>01</month><year>2018</year></pub-date><volume>7</volume><elocation-id>e32724</elocation-id><history><date date-type="received"><day>12</day><month>10</month><year>2017</year></date><date date-type="accepted"><day>03</day><month>01</month><year>2018</year></date></history><permissions><copyright-statement>Â© 2018, Strutt et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Strutt et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-32724-v1.pdf"/><abstract><p>Double-stranded DNA (dsDNA) binding and cleavage by Cas9 is a hallmark of type II CRISPR-Cas bacterial adaptive immunity. All known Cas9 enzymes are thought to recognize DNA exclusively as a natural substrate, providing protection against DNA phage and plasmids. Here we show that Cas9 enzymes from both subtypes II-A and II-C can recognize and cleave single-stranded RNA (ssRNA) by an RNA-guided mechanism that is independent of a protospacer-adjacent motif (PAM) sequence in the target RNA. RNA-guided RNA cleavage is programmable and site-specific, and we find that this activity can be exploited to reduce infection by single-stranded RNA phage <italic>in vivo</italic>. We also demonstrate that Cas9 can direct PAM-independent repression of gene expression in bacteria. These results indicate that a subset of Cas9 enzymes have the ability to act on both DNA and RNA target sequences, and suggest the potential for use in programmable RNA targeting applications.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>E. coli</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Torrez</surname><given-names>Rachel M</given-names></name><name><surname>Doudna</surname><given-names>Jennifer A</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>MCB-1244557</award-id><principal-award-recipient><name><surname>Strutt</surname><given-names>Steven C</given-names></name><name><surname>Doudna</surname><given-names>Jennifer A</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>Paul Allen Frontiers Science Program</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Doudna</surname><given-names>Jennifer A</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007000</institution-id><institution>Laboratory Directed Research and Development</institution></institution-wrap></funding-source><award-id>U.S. Department of Energy's National Nuclear Security Administration under contract DE-NA0003525</award-id><principal-award-recipient><name><surname>Negrete</surname><given-names>Oscar A</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution>German Academic Exchange Program</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Kaya</surname><given-names>Emine</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Steven C Strutt, is listed on a patent application (No. 62598888) related to this work.</p></fn><fn fn-type="conflict" id="conf3"><p>Oscar A Negrete, is listed on a patent application (No. 62598888) related to this work.</p></fn><fn fn-type="conflict" id="conf4"><p>Jennifer A Doudna, is a co-founder of to Caribou Biosciences, Intellia Therapeutics, and Editas Medicine and a scientific advisor to Caribou, Intellia, eFFECTOR Therapeutics and Driver. JAD is listed on a patent application (No. 62598888) related to this work.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="datasets"><title>Major datasets</title><p/><p>The following datasets were generated:</p><p><related-object content-type="generated-dataset" id="dataro1" source-id="https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA413805" source-id-type="uri"><collab>Steven Strutt</collab>, <collab>Jennifer Doudna</collab>, <year>2017</year><x>,</x> <source>MS2 CRISPR screen in E. coli</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA413805">https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA413805</ext-link><x>,</x> <comment>Publicly available at NCBI SRA under the BioProject accession number PRJNA413805</comment></related-object></p></sec><supplementary-material><ext-link xlink:href="elife-32724-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>